Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

Clin Pharmacokinet. 2022 Jun;61(6):919. doi: 10.1007/s40262-022-01134-1.

¹ Clinical Pharmacology and PharmacometricsAlnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA. [email protected].
² Agios Pharmaceuticals, Cambridge, MA, USA.
³ Clinical Pharmacology and PharmacometricsAlnylam Pharmaceuticals, 101 Main Street, Cambridge, MA, 02142, USA.
⁴ Alexion Pharmaceuticals, Boston, MA, USA.

No abstract available

Publication types